Solasia Of Japan, Ziopharm Of U.S. In $86 Million Cancer Drug Deal
This article was originally published in PharmAsia News
Executive Summary
Japan's Solasia Pharma has reached an agreement with U.S. drug maker Ziopharm Oncology to develop a cancer drug for the Asian and Pacific markets